Chalcones as positive allosteric modulators of α7 nicotinic acetylcholine receptors: A new target for a privileged structure

European Journal of Medicinal Chemistry

Volumn 86, Issue , 2014, Pages 724-739

  Balsera, Beatriz ^a   Mulet, José ^b   Fernández Carvajal, Asia ^b   Torre Martínez, Roberto De La ^b   Ferrer Montiel, Antonio ^b   Hernández Jiménez, José G ^c   Estévez Herrera, Judith ^c   Borges, Ricardo ^c   Freitas, Andiara E ^d   López, Manuela G ^d   García López, M Teresa ^a   González Muñiz, Rosario ^a   Pérez De Vega, María Jesús ^a   Valor, Luis M ^b   Svobodová, Lucie ^b   Sala, Salvador ^b   Sala, Francisco ^b   Criado, Manuel ^b  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c UNIVERSIDAD DE LA LAGUNA   (Spain)

^d INSTITUTO TEÓFILO HERNANDO   (Spain)

Author keywords

Analgesia; Chalcones; Neuroprotection; Positive allosteric modulators; 7 Nicotinic receptor

Indexed keywords

(E) 1 (2',5' DIHYDROXYPHENYL) 3 (2 HYDROXY 4,6 DIMETOXYPHENYL) 2 PROPEN 1 ONE; (E) 1 (2',5' DIHYDROXYPHENYL) 3 (2,4 DIHYDROXYPHENYL) 2 PROPEN 1 ONE; (E) 1 (2',5' DIHYDROXYPHENYL) 3 (2,4 DIMETHOXYPHENYL) 2 PROPEN 1 ONE; (E) 1 (2',5' DIHYDROXYPHENYL) 3 (2,6 DIHYDROXY 4 METHOXYPHENYL) 2 PROPEN 1 ONE; (E) 1 (2',5' DIHYDROXYPHENYL) 3 (2,6 DIHYDROXYPHENYL) 2 PROPEN 1 ONE; (E) 1 (2',5' DIHYDROXYPHENYL) 3 (5 HYDROXY 1H INDOL 3 YL) 2 PROPEN 1 ONE; (E) 3 (2 HYDROXYPHENYL) 1 (2',4',5' TRIHYDROXYPHENYL) 2 PROPEN 1 ONE; (E) 3 (2,4 DIHYDROXYPHENYL) 1 (2' HYDROXYPHENYL) 2 PROPEN 1 ONE; (E) 3 (2,4 DIHYDROXYPHENYL) 1 (2',4',5' TRIHYDROXYPHENYL) 2 PROPEN 1 ONE; (E) 3 (2,4 DIHYDROXYPHENYL) 1 (3' HYDROXYPHENYL) 2 PROPEN 1 ONE; (E) 3 (2,4 DIHYDROXYPHENYL) 1 (4' HYDROXYPHENYL) 2 PROPEN 1 ONE; (E) 3 (4 ACETYLAMINOPHENYL) 1 (2',5' DIHYDROXYPHENYL) 2 PROPEN 1 ONE; (E) 3 (4 AMINOPHENYL) 1 (2',5' DIHYDROXYPHENYL) 2 PROPEN 1 ONE; (Z) 1 (2',5' DIHYDROXYPHENYL) 3 (2,4 DIHYDROXYPHENYL) 2 PROPEN 1 ONE; (Z) 3 (2,4 DIHYDROXYPHENYL) 1 (3' HYDROXYPHENYL) 2 PROPEN 1 ONE; (Z) 3 (2,4 DIHYDROXYPHENYL) 1 (4' HYDROXYPHENYL) 2 PROPEN 1 ONE; ANALGESIC AGENT; BUNGAROTOXIN RECEPTOR; CHALCONE DERIVATIVE; HYDROXYL GROUP; ISOLIQUIRITIGENIN; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG; OLIGOMYCIN; ROTENONE;

ALLOSTERISM; ANALGESIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CATALYSIS; COGNITION; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; NEUROPROTECTION; PROTON NUCLEAR MAGNETIC RESONANCE; THIN LAYER CHROMATOGRAPHY; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; CELL DEATH; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; MALE; MAZE TEST; METABOLISM; MOUSE; PAIN; RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS; WISTAR RAT;

ALLOSTERIC REGULATION; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; CELL DEATH; CELL SURVIVAL; CHALCONES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MAZE LEARNING; MICE; MOLECULAR STRUCTURE; OLIGOMYCINS; PAIN; RATS; RATS, WISTAR; ROTENONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84907822172     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.09.039     Document Type: Article

References (59)

1. R.L. Papke, Merging old and new perspectives on nicotinic acetylcholine receptors, Biochem. Pharmacol. 89 (2014) 1-11.
2. E.X. Albuquerque, E.F.R. Pereira, M. Alkondon, S.W. Rogers, Mammalian nicotinic acetylcholine receptors: from structure to function, Physiol. Rev. 89 (2009) 73-120.
3. D.K. Berg, W.G. Conroy, Nicotinic α7 receptors: synaptic options and downstream signaling in neurons, J. Neurobiol. 53 (2002) 512-523.
4. H.R. Parri, C.M. Hernandez, K.T. Dineley, Research update: alphα7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease, Biochem. Pharmacol. 82 (2011) 931-942.
5. B. Lendvai, F. Kassai, A. Szájli, Z. Némethy, α7 Nicotinic acetylcholine receptors and their role in cognition, Brain Res. Bull. 93 (2013) 86-96.
6. J.W. Young, M.A. Geyer, Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia, Biochem. Pharmacol. 86 (2013) 1122-1132.
7. I.C. Umana, C.A. Daniele, D.S. McGehee, Neuronal nicotinic receptors as analgesic targets: It's a winding road, Biochem. Pharmacol. 86 (2013) 1208-1214.
8. G. Matteoli, G.E. Boeckxstaens, The vagal innervation of the gut and immune homeostasis, Gut 62 (2013) 1214-1222.
9. J.L. Galzi, S. Bertrand, P.-J. Corringer, J.-P. Changeux, D. Bertrand, Identification of calcium binding sites that regulate potentiation of a neuronal nicotinic acetylcholine receptor, EMBO J. 15 (1996) 5824-5832.
10. V.V. Uteshev, The therapeutic promise of positive allosteric modulation of nicotinic receptors, Eur. J. Pharmacol. 727 (2014) 181-185.
11. F. Chimienti, R.C. Hogg, L. Plantard, C. Lehmann, N. Brakch, J. Fischer, M. Huber, D. Bertrand, D. Hohl, Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda, Hum. Mol. Genet. 12 (2003) 3017-3024.
12. R.S. Hurst, M. Hajós, M. Raggenbass, T.M. Wall, N.R. Higdon, J.A. Lawson, K.L. Rutherford-Root, M.B. Berkenpas, W.E. Hoffmann, D.W. Piotrowski, V.E. Groppi, G. Allaman, R. Ogier, S. Bertrand, D. Bertrand, S.P. Arneric, A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization, J. Neurosci. 25 (2005) 4396-4405.
13. D.K. Williams, J. Wang, R.L. Papke, Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations, Biochem. Pharmacol. 82 (2011) 915-930.
14. S. Kumar, A. Sharma, B. Madan, V. Singhal, B. Ghosg, Isoliquiritigenin inhibits IkB kinase activity and ROS generation to block TNF-α induced expression of cell adhesion molecules on human endothelial cells, Biochem. Pharmacol. 73 (2007) 1602-1612.
15. J. Vaya, P.A. Belinky, M. Aviram, Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation, Free Radic. Biol. Med. 23 (1997) 302-313.
16. H. Kakegawa, H. Matsumoto, T. Satoh, Inhibitory effects of some natural products on the activation of hyaluronidase and their anti-allergic actions, Chem. Pharm. Bull. 40 (1992) 1439-1442.
17. S. Yamazaki, T. Morita, H. Endo, T. Hamamoto, M. Baba, Y. Joichi, S. Kaneko, Y. Okada, T. Okuyama, H. Nishini, A. Tokue, Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma, Cancer Lett. 183 (2002) 23-30.
18. T. Takahashi, N. Takasuka, M. Iigo, M. Baba, H. Nishino, H. Tsuda, T. Okuyama, Isoliquiritigenin, a flavonoid from licorice, reduces prostaglandin -2 and nitric oxide, causes apoptosis, and suppresses aberrant crypt foci development, Cancer Sci. 95 (2004) 448-453.
19. C. Zhan, J. Yang, Protective effects of isoliquiritigenin in transient middle cerebral artery occlusion-induced focal cerebral ischemia in rats, Pharmacol. Res. 53 (2006) 303-309.
20. M.J. Lee, C.H. Yang, J.-P. Jeon, M. Hwang, Protective effects of isoliquiritigenin against methamphetamine-induced neurotoxicity in mice, J. Pharmacol. Sci. 111 (2009) 216-220.
21. A. Campos-Caro, F.I. Smillie, E. Domínguez del Toro, J.C. Rovira, F. Vicente-Agulló, J. Chapuli, J.M. Juíz, S. Sala, F. Sala, J.J. Ballesta, M. Criado, Neuronal nicotinic acetylcholine receptors on bovine chromaffin cells: cloning expression and genomic organization of receptor subunits, J. Neurochem. 68 (1997) 488-497.
22. S. Khatib, O. Nerya, R. Musa, M. Shmuel, S. Tamir, J. Vaya, Chalcones as potent tyrosinase inhibitors: the importance of a 2,4-substituted resorcinol moiety, Bioorg. Med. Chem. 13 (2005) 433-441.
23. J.F.W. McOmie, M.L. Watts, D.E. West, Demethylation of aryl methyl ethers by boron tribromide, Tetrahedron 24 (1968) 2289-2292.
24. C. Chiruta, D. Schubert, R. Dargusch, P. Maher, Chemical modification of the multitarget neuroprotective compound Fisetin, J. Med. Chem. 55 (2012) 378-389.
25. D. Huang, J.-X. Wang, Y. Hu, Y. Zhang, J. Tang, A new solvent-free synthesis of a,b-unsaturated ketones from acetals with aryl ketones under microwave irradiation, Synth. Commun. 32 (2002) 971-979.
26. T. Narender, K. Papi Reddy, A simple and highly efficient method for the synthesis of chalcones by using borontrifluoride-etherate, Tet. Lett. 48 (2007) 3177-3180.
27. B.-T. Kim, K.-J. O, J.-C. Chun, K.-J. Hwang, Synthesis of dihydroxylated chalcone derivatives with diverse substitution patterns and their radical scavenging ability toward DPPH free radicals, Bull. Korean Chem. Soc. 29 (2008) 1125-1130.
28. J. Mai, E. Hoxha, C.E. Morton, B.M. Muller, M.J. Adler, Towards a dynamic covalent molecular switch: substituent effects in chalcone/flavanone isomerism, Org. Biomol. Chem. 11 (2013) 3421-3423.
29. M.S. Thomsen, J.D. Mikkelsen, Type I and II positive allosteric modulators differentially modulate agonist-induced up-regulation of α7 nicotinic acetylcholine receptors, J. Neurochem. 123 (2012) 73-83.
30. J.H. Grønlien, M. Hakerud, H. Ween, K. Thorin-Hagene, C.A. Briggs, M. Gopalakrishnan, J. Malysz, Distinct profiles of alpha 7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes, Mol. Pharmacol. 72 (2007) 715-724.
31. P. Perjési, M. Takács, E. Osz, Z. Pintér, J. Vámos, K. Takács-Novák, In-solution and on-plate light-Catalyzed E/Z isomerization of Cyclic chalcone analogues. Lipophilicity of E-and Z-2-(X-Benzylidene)-1-Benzosuberones, J. Chromatogr. Sci. 43 (2005) 289-295.
32. S. Iwata, T. Nishino, H. Inoue, N. Nagata, Y. Satomi, H. Nishino, S. Shibata, Antitumorigenic activities of chalcones (II). Photo-isomerization of chalcones and the correlation with their biological activities, Biol. Pharm. Bull. 20 (1997) 1266-1270.
33. J. Malysz, J.H. Grønlien, D.J. Anderson, M. Hakerud, K. Thorin-Hagene, H. Ween, C. Wetterstrand, C.A. Briggs, R. Faghih, W.H. Bunnelle, M. Gopalakrishnan, In vitro pharmacological characterization of a novel allosteric modulator of α7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methyl-3-propionyl-1H-pyrrol-1-yl)benzenesulfonamide (A-867744), exhibiting unique pharmacological profile, J. Pharm. Exp. Ther. 330 (2009) 257-267.
34. J. Amanaganti, N.J.P. Subhashini, Potential biological activity of chalcones: a review, J. Chem. Sci. 11 (2013) 1335-1341.
35. L. Wu, M.H.N. Ashraf, M. Facci, R. Wang, G. Phyllis, P.G. Paterson, A. Ferrie, B.H.J. Juurlink, Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system, Proc. Natl. Acad. Sci. U S A 101 (2004) 7094-7099.
36. J. Egea, A.O. Rosa, A. Cuadrado, A.G. Garcia, M.G. Lopez, Nicotinic receptor activation by epibatidine induces heme oxygenase-1 and protects chromaffin cells against oxidative stress, J. Neurochem 102 (2007) 1842-1852.
37. J. Liu, L. Li, W.Z. Suo, HT22 hippocampal neuronal cell line possesses functional cholinergic properties, Life Sci. 84 (2009) 267-271.
38. E. Parada, J. Egea, A. Romero, L. del Barrio, A.G. García, M.G. López, Poststress treatment with PNU-282987 can rescue SH-SY5Y cells undergoing apoptosis via α7 nicotinic receptors linked to a Jak2/Akt/HO-1 signaling pathway, Free Radic. Biol. Med. 49 (2010) 1815-1821.
39. E. Parada, J. Egea, I. Buendia, P. Negredo, A.C. Cunha, S. Cardoso, M.P. Soares, M.G. López, The microglial α7-acetylcholine nicotinic receptor is a key element in promoting neuroprotection by inducing heme oxygenase-1 via nuclear factor erythroid-2-related factor 2, Antioxid. Redox Signal 19 (2013) 1135-1148.
40. R. Roncarati, C. Scali, T.A. Comery, S.M. Grauer, S. Aschmi, H. Bothmann, B. Jow, D. Kowal, M. Gianfriddo, C. Kelley, U. Zanelli, C. Ghiron, S. Haydar, J. Dunlop, G.C. Terstappen, Procognitive and neuroprotective activity of a novel alphα7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders, J. Pharmacol. Exp. Ther. 329 (2009) 459-468.
41. S. Suzuki, J. Kawamata, T. Matsushita, A. Matsumura, S. Hisahara, K. Takata, Y. Kitamura, W. Kem, S. Shimohama, 3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nicotinic acetylcholine receptor stimulation in rats, J. Neurosci. Res. 91 (2013) 462-471.
42. L. Del Barrio, M.D. Martín-de-Saavedra, A. Romero, E. Parada, J. Egea, J. Avila, J.M. McIntosh, S. Wonnacott, M.G. López, Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by α7 and b2∗nicotinic stimulation, Toxicol. Sci. 123 (2011) 193-205.
43. H.V. Nobre-Júnior, R.A. Oliveira, F.D. Maia, M.A. Nogueira, M.O. de Moraes, M.A. Bandeira, G.M. Andrade, G.S. Viana, Neuroprotective effects of chalcones from Myracrodruon urundeuva on 6-hydroxydopamine-induced cytotoxicity in rat mesencephalic cells, Neurochem. Res. 34 (2009) 1066-1075.
44. G. Munro, R. Hansen, H. Erichsen, D. Timmermann, J. Christensen, H. Hansen, The alphα7 nicotinic ACh receptor agonist compound B and positive allosteric modulator PNU-120596 both alleviate inflammatory hyperalgesia and cytokine release in the rat, Br. J. Pharmacol. 167 (2012) 421-435.
45. K. Freitas, F.I. Carroll, M.I. Damaj, The antinociceptive effects of nicotinic receptors alphα7-positive allosteric modulators in murine acute and tonic pain models, J. Pharmacol. Exp. Ther. 344 (2013) 264-275.
46. K. Freitas, S.S. Negus, F.I. Carroll, M.I. Damaj, In vivo pharmacological interactions between a type II positive allosteric modulator of alphα7 nicotinic ACh receptors and nicotinic agonists in a murine tonic pain model, Br. J. Pharmacol. 169 (2013) 567-579.
47. Y. Nagakura, M. Okada, A. Kohara, T. Kiso, T. Toya, I. Akihiko, F. Wanibuchi, T. Yamaguchi, Allodynia and hyperalgesia in adjuvant-induced arthritic rats: time course of progression and efficacy of analgesics, J. Pharmacol. Exp. Ther. 306 (2003) 490-497.
48. S. Sogawa, Y. Nihro, H. Ueda, A. Izumi, T. Miki, H. Matsumoto, T. Satoh, 3,4-Dihydroxychalcones as potent 5-lipoxygenase and cyclooxygenase inhibitors, J. Med. Chem. 36 (1993) 3904-3909.
49. H.K. Hsieh, T.H. Lee, J.P. Wang, J.J. Wang, C.N. Lin, Synthesis and anti e inflammatory effect of chalcones and related compounds, Pharm. Res. 15 (1998) 39-46.
50. S.L. McLean, N. Idris, B. Grayson, D. Gendle, C. Mackie, A. Lesage, D.J. Pemberton, J. Neill, PNU-120596. a positive allosteric modulator of α7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidineinduced cognitive deficit in the attentional set-shifting task in female rats, J. Psychopharmacol. 26 (2012) 1265-1270.
51. M. Criado, L.M. Valor, J. Mulet, S. Gerber, S. Sala, F. Sala, Expression and functional properties of α7 acetylcholine nicotinic receptors are modified in the presence of other receptor subunits, J. Neurochem 123 (2012) 504-514.
52. N. Dominguez, M. Rodriguez, J.D. Machado, R. Borges, Preparation and culture of adrenal chromaffin cells, Methods Mol. Biol. 846 (2012) 223-234.
53. J.D. Machado, M.S. Montesinos, R. Borges, Good practices in single cell amperometry, Methods Mol. Biol. 440 (2008) 297-313.
54. F. Segura, M.A. Brioso, J.F. Gomez, J.D. Machado, R. Borges, Automatic analysis for amperometrical recordings of exocytosis, J. Neurosci. Methods 103 (2000) 151-156.
55. T. Mosmann, Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays, J. Immunol. Methods 65 (1983) 55-63.
56. F. Denizot, R. Lang, Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability, J. Immunol. Methods 89 (1986) 271-277.
57. C. García-Martínez, A. Fernández-Carvajal, B. Valenzuela, A. Gomis, W. Van Den Nest, S. Ferroni, C. Carreno, C. Belmonte, A. Ferrer-Montiel, Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and antiinflammatory activity, J. Pain 7 (2006) 735-746.
58. C.V. Vorhees, M.T. Williams, Morris water maze: procedures for assessing spatial and related forms of learning and memory, Nat. Protoc. 1 (2006) 848-858.
59. D. Pereda, M.R. Pardo, Y. Morales, N. Dominguez, M.R. Arnau, R. Borges, Phenotypic characterization of mice lacking chromogranins. (Unpublished results).